Hui-Qing LIU, M.D. & Ph.D.
Associate professor
Instituteof Pharmacology
Schoolof BasicMedical Sciences
ShandongUniversity
44# West Wenhua Road
Jinan, Shandong250012
P. R. China
Tel:86-0531-88382605(O)
86-15853170726(cell)
E-mail Adress:liuhuiqing@sdu.edu.cn
Birth Date:January 8, 1976
EDUCATION
School of Medicine, Shandong University, Jinan, P.R.China.
Ph. D. in Pharmacology, June 2005
Emphasis: cardiovascular pharmacology
School of Medicine, Shandong University, Jinan, P.R.China
M.S. in Pharmacology, June 2001
Emphasis: Cardiovascular pharmacology
ShandongMedical University, Jinan, P.R.China
M.D., June 1998
Emphasis: Clinical medicine
WORKING EXPERIENCE
November 2008 – December 2009
Postdoc training & Visiting Scholar,
Experimental Cardiovascular Research, Center for Molecular Medicine L8:03，Karolinska Institute，Sweden
September 2007 - Present
Associate professor,
Instituteof Pharmacology, School of Medicine, Shandong University, Jinan, P.R.China.
September 2003 – September 2007
Assistant professor (instructor),
Instituteof Pharmacology, School of Medicine, Shandong University, Jinan, P.R.China.
July 2001- September 2003
Teaching and Research Assistant,
Instituteof Pharmacology, School of Medicine, Shandong University, Jinan, P.R.China.
TECHNIQUES
Cell Culture:Mammalian cell culture including endothelial cell, smooth muscle cell, astrocytes, microglia, neuron, monocyte, etc.
Ex vivoatherosclerotic plaque tissue culture
Animal(rabbits, rats, mice):
1)Model: Rat and mouse model of middle cerebral artery occlusion (MCAO)
Mouse model of Parkinson’s disease by sterotactic injection of 6-OHDA, or subcutaneous injection of MPTP
Test the acute and chronic toxicity of new compounds
2)Various routes of drug administration: subcutaneous, intramuscular, intravenous, intraperitoneal and intragastric)
Molecular Biology:PCR, real time RT-PCR, Western blot,immunohistochemistry, siRNA transfection, EMSA, Co-IP, ELLSA, TUNEL staining, etc.
Computer: Word, PowerPoint, Excel, and conversant with internet-based literature searches. Experienced in software such as Endnote, SPSS, Graphpad prism 6, Adobe photoshop etc.
Writing:Experienced in writing papers in English.
FUNDINGS
1. The role and molecular mechanism of TRIM31 in Parkinson's disease by regulating mitochondrial homeostasis, National Natural Science Foundation of China(No. 81971193).
2. The role and regulation mechanism of NOD2 mediated immune inflammation in Parkinson's disease, National Natural Science Foundation of China(No. 81571171).
3. The role and mechanism ofNADPH oxidase in NOD2-mediated cerebral ischemia-reprfusion injury. National Natural Science Foundation ofChina(No.81200904).
4. The effect andpossible mechanism ofCXC195, a novel Tetramethylpyrazine derivative, on neurovascular unit in cerebral ischemia-reperfusion injury.ShandongProvinceScience and Technology Plan (No.2014GWZ20246).
5. Themechanism ofangiotensin II incerebralischemia-reperfusioninjury and theprotectiveeffect of anovel AT1receptorantagonist EXP-2528. National Natural Science Foundation ofChina(No.30572187)
Publications
1.Chen L, Kong L, Wei X, Wang Y, Wang B, Zhang X, Sun J,Liu H*. β-arrestin 2 negatively regulates NOD2 signalling pathway through association with TRAF6 in microglia after cerebral ischaemia/reperfusion injury.J Cell Mol Med.2019;23(5):3325-3335..
2.Ren Z, Chen L, Wang Y, Wei X, Zeng S, Zheng Y, Gao C*,Liu H*.Activation of the Omega-3 Fatty Acid Receptor GPR120 Protects against Focal Cerebral Ischemic Injury by Preventing Inflammation and Apoptosis in Mice.J Immunol.2019; 202(3):747-759.
3.Cheng L, Chen L, Wei X, Wang Y, Ren Z, Zeng S, Zhang X, Wen H, Gao C,Liu H*. NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson's disease.J Neuroinflammation.2018; 15(1): 243.
4.Chen L, Ren Z, Wei X, Wang S, Wang Y, Cheng Y, Gao H,Liu H*.
Losartan protects against cerebral ischemia/reperfusion-induced apoptosis through β-arrestin1-mediated phosphorylation of Akt.Eur J Pharmacol.2017; 815: 98-108.
5.Liu H, Wei X，Kong L, Cheng L, Yan S，Zhang X, Chen L. NOD2 is involved in the inflammatory response after cerebral ischemia- reperfusion injury and triggers NADPH oxidase 2-derived reactive oxygen species.Int. J. Biol. Sci.2015; 11(5): 525-35.
6.Yan S, Chen L, Wei X, Cheng L, Kong L, Liu X, Zhang X,Liu H*. Tetramethylpyrazine analogue CXC195 ameliorates cerebral ischemia-reperfusion injury by regulating endothelial nitric oxide synthase phosphorylation via PI3K/Akt signaling.Neurochem Res.2015; 40(3): 446-54.
7. Chen L, Wei X, Hou Y, Liu X, Li S, Sun B, Liu X,Liu H*. Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion-induced apoptosis through PI3K/Akt/GSK3βpathway in rats.Neurochem Int.2014; 66: 27-32.
8.Liu H, Zhang XY, Edfeldt K, Nijhuis MO, Idborg H, Bäck M, Roy J, Hedin U, Jakobsson PJ, Laman JD, de Kleijn DP, Pasterkamp G, Hansson GK, Yan ZQ. NOD2-Mediated Innate Immune Signaling Regulates the Eicosanoids in Atherosclerosis.Arterioscler Thromb Vasc Biol. 2013;33(9):2193-2201.
9. Wei C, Kong L, Wei X, Chen L, Liu X, Zhang X, Liu X,Liu H*. Pharmacokinetics of a New Tetramethylpyrazine Analogue CXC195 in Rats.Drug Res (Stuttg).2013: 63(7): 342-5.
10.Liu H, Liu X, Wei X, Chen L, Xiang Y, Yi F, Zhang X. Losartan, an angiotensin II type 1 receptor blocker, ameliorates cerebral ischemia-reperfusion injury via PI3K/Akt-mediated eNOS phosphorylation.Brain Res Bull.2012; 89(1-2): 65-70.
11. Ketelhuth D, Rios F, Wang Y,Liu H, Johansson ME, Fredrikson GF, Hedin U, Gidlund M, Nilsson J, Hansson GK, Yan ZQ. Identification of a danger-associated peptide from apolipoprotein B100 (ApoBDS-1) that triggers innate pro-atherogenic responses.Circulation. 2011, 124(22): 2433-43.
12.Liu H, Wei X, Chen L, Liu X, Xiang Y, Liu X , Zhang X*. Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion injury in the rat by an antioxidant action via inhibition of NADPH oxidase and iNOS expression.Phamacology,2013; 92(3-4):198-206.
